Lee Young-shin, vice chairman of the Korea International Association of Pharmaceutical Industries (KRPIA), said, "The government and numerous stakeholders in the health and medical sector, including the pharmaceutical industry, should join forces before the pre-emptive task of rapidly expanding new drug treatment opportunities for Korean patients."
KRPIA Vice Chairman Lee Young-shin said in his "2024 New Year's Address" on the 20th, "Despite the steady efforts of the government and industry, numerous patients with severe and rare diseases are still suffering from problems with access to treatment."
"KRPIA will also cooperate with the government and other stakeholders so that treatment benefits can be provided to more people within the limited health insurance budget, and patients can experience proper and prompt treatment and new lives," he said.
It also showed its intention to actively participate in supporting the growth of the pharmaceutical industry to improve the quality of the domestic treatment environment.
"Global pharmaceutical companies are practicing the value of win-win through various open innovation investments such as expanding the scale of domestic clinical trials, cooperation with domestic companies and institutions, and operation of support programs," Vice Chairman Lee said. "When the pharmaceutical industry builds an R&D ecosystem through continuous collaboration with the domestic industry, the entire industry's capabilities grow."
"In an era of crisis in which social contraction is feared due to low birthrates, we will respect diversity and lead a family-friendly corporate culture and transparent and healthy management so that we can contribute to Korea's future growth beyond industrial development," he added.
[WIKI KOREA=Cho Eun, Reporter]
choeun@wikileaks-kr.org
